sabizabulin

Sabizabulin is an orally bioavailable, small molecule tubulin inhibitor developed as a first-in-class microtubule disruptor with antineoplastic, antiviral, and anti-inflammatory activities. It binds to the colchicine-binding site on beta-tubulin and a unique site on alpha-tubulin, crosslinking these subunits to inhibit microtubule polymerization. This action leads to disruption of the mitotic spindle, cell cycle arrest at G2/M phase, apoptosis in tumor cells, and inhibition of tumor vasculature formation. Sabizabulin also impairs intracellular transport processes critical for androgen receptor nuclear translocation (relevant in prostate cancer) and viral trafficking (including SARS-CoV-2), thereby reducing viral replication and assembly. Additionally, it suppresses pro-inflammatory cytokine release by disrupting inflammatory cell activity. Sabizabulin is not a substrate for P-glycoprotein or CYP3A4 enzymes[1][2][3][4][5][6].

Other names

sabizabulin